Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges

Kunimasa, Kei; Goto, Taichiro

doi:10.3390/ijms21020597

Cited by 65 publications

(50 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other words, to avoid an immune attack, tumor cells attempt to escape the immune surveillance by editing the tumor microenvironment. Additionally, tumor cells attempt to evade immune recognition; the loss of antigen on tumor cell surfaces allows tumor cells to avoid recognition by cytotoxic T cells [ 172 ]. The inhibitory receptor cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is constitutively expressed on regulatory T cells (Tregs) [ 173 ], while it is transiently expressed on activated T cells [ 174 ].…”

Section: Applications Of Irgd In Cancer Therapymentioning

confidence: 99%

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

2020

View full text Add to dashboard Cite

The unique structure and physiology of a tumor microenvironment impede intra-tumoral penetration of chemotherapeutic agents. A novel iRGD peptide that exploits the tumor microenvironment can activate integrin-dependent binding to tumor vasculatures and neuropilin-1 (NRP-1)-dependent transport to tumor tissues. Recent studies have focused on its dual-targeting ability to achieve enhanced penetration of chemotherapeutics for the efficient eradication of cancer cells. Both the covalent conjugation and the co-administration of iRGD with chemotherapeutic agents and engineered delivery vehicles have been explored. Interestingly, the iRGD-mediated drug delivery also enhances penetration through the blood–brain barrier (BBB). Recent studies have shown its synergistic effect with BBB disruptive techniques. The efficacy of immunotherapy involving immune checkpoint blockades has also been amplified by using iRGD as a targeting moiety. In this review, we presented the recent advances in iRGD technology, focusing on cancer treatment modalities, including the current clinical trials using iRGD. The iRGD-mediated nano-carrier system could serve as a promising strategy in drug delivery to the deeper tumor regions, and be combined with various therapeutic interventions due to its novel targeting ability.

show abstract

Section: Applications Of Irgd In Cancer Therapymentioning

confidence: 99%

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

2020

View full text Add to dashboard Cite

show abstract

“…A small number of cancer cells in the body are usually attacked and eliminated by the antitumor immune mechanism [92]. However, this mechanism may gradually malfunction as cancer cells grow.…”

Section: Effect Of Microbes On Cancer Immunotherapymentioning

confidence: 99%

Airway Microbiota as a Modulator of Lung Cancer

Goto

2020

IJMS

Self Cite

View full text Add to dashboard Cite

Recent research on cancer-associated microbial communities has elucidated the interplay between bacteria, immune cells, and tumor cells; the bacterial pathways involved in the induction of carcinogenesis; and their clinical significance. Although accumulating evidence shows that a dysbiotic condition is associated with lung carcinogenesis, the underlying mechanisms remain unclear. Microorganisms possibly trigger tumor initiation and progression, presumably via the production of bacterial toxins and other pro-inflammatory factors. The purpose of this review is to discuss the basic role of the airway microbiome in carcinogenesis and the underlying molecular mechanisms, with the aim of developing anticancer strategies involving the airway microbiota. In addition, the mechanisms via which the microbiome acts as a modulator of immunotherapies in lung cancer are summarized.

show abstract

“…Author details 1 The First Medical Center of PLA General Hospital, Department of Radiation Oncology, Beijing, P.R. China.…”

Section: Declarationsmentioning

confidence: 99%

“…Non-small cell lung cancer (NSCLC) is an aggressive subtype of lung cancer with high mortality and morbidity, which includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [1].…”

Section: Introductionmentioning

confidence: 99%

MMP10 involved in Radiosensitivity in Non-Small Cell Lung Cancer via DNA damage repair pathway

Lei

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Non-small cell lung cancer (NSCLC) is an aggressive subtype of lung cancer with high mortality and morbidity. Our purpose in this study is to investigate the effect of MMP10 in NSCLC during radiotherapy and its mechanism. Materials and methods We analyzed MMP10 expression and overall survival rate of patients via UALCAN analysis. Western blot analysis was used to test the protein expression. We applied clonogenic assay and apoptosis assay to detect radioresistance in vitro. The level of DNA damage and the DNA damage repair were disclosed via comet assay and γH2AX foci assay. Results Our results showed that high MMP10 expression in Lung Adenocarcinoma specimens is associated with poor outcomes of patients. Knockdown MMP10 induced radiosensitization in A549 cells via clonogenic assay and apoptosis assay. Furthermore, we found MMP10 siRNA enhanced DNA damage of NSCLC cells and MMP10 involved in DNA damage repair after IR. Conclusion Our data highlighted that MMP10 plays a crucial role in NSCLC after radiation via DNA damage repair pathway, and the regulating effect of MMP10 on radiosensitivity in NSCLC might confer to therapeutic implications to NSCLC radiotherapy.

show abstract

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges

Cited by 65 publications

References 204 publications

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

Airway Microbiota as a Modulator of Lung Cancer

MMP10 involved in Radiosensitivity in Non-Small Cell Lung Cancer via DNA damage repair pathway

Contact Info

Product

Resources

About